Background: Lenalidomide has immunomodulatory and anti-angiogenic effects and
| INTRODUCTION
Treatment of advanced-stage hepatocellular carcinoma (HCC), defined as patients with macrovascular invasion or extrahepatic metastases, barcelona clinic liver cancer (BCLC) stage C, remains a great challenge. Sorafenib is currently the only approved first-line therapy for advanced HCC, with a median time to progression of 2-3 months and overall survival of 7-11 months. 1 Patients whose tumours progressed after sorafenib treatment may survive for more than 6 months if they have Child-Pugh A liver function reserves and are potentially eligible for clinical trials. 2, 3 Therefore, second-line systemic therapy for advanced HCC is a huge unmet medical need.
Two major classes of systemic therapy have shown promising anti-tumour activity as second-line therapy for advanced HCC. The first class is anti-angiogenic therapy. The multi-kinase inhibitor regorafenib, which is a more potent inhibitor than sorafenib against vascular endothelial growth factor receptor and RAF kinases, has been found to prolong overall survival in HCC patients whose tumours progressed after sorafenib treatment. 4 Ramucirumab, a monoclonal antibody against vascular endothelial growth factor receptor, may prolong survival as second-line therapy for HCC patients with elevated a-fetoprotein level. 5 The second class is immunotherapy. A phase I/II study of the checkpoint inhibitor nivolumab reported an objective tumour response rate of 10%-20%, median progressionfree survival of 4 months, and 9-month overall survival rate of 74% in advanced HCC patients who progressed on or were intolerant to sorafenib treatment. 6 Combinations of these two classes of agents have shown potential synergistic anti-tumour effects in pre-clinical models. 7 Lenalidomide and its antecedent agent thalidomide have both anti-angiogenic and immunomodulatory property. 8, 9 Recent studies have delineated the complex effects of thalidomide and lenalidomide on lymphocyte activation and modulation of tumour micro-environment. 10, 11 
| Statistical analyses
The primary endpoint was 6-month progression-free survival rate.
The secondary endpoints included objective response (complete or partial response according to RECIST1.1), overall survival and safety.
The disease-control rate was defined as complete or partial response or durable ( ≥ 8 weeks) stable disease according to RECIST1.1. The
Chi square test (or Fisher exact test when appropriate) was used to analyse the potential associations between objective response rate or disease-control rate and nominal variables. Progression-free survival and overall survival were analysed using the Kaplan-Meier method. Univariate analysis to examine the value of individual biomarkers for predicting progression-free or overall survival was done using the log rank test. A Cox's proportional hazards model was utilised to calculate hazard ratios (HRs) for progression-free and overall survival and examine potential predictors for progression-free and overall survival after adjustment for age, patient sex, underlying viral infection, performance status, The Cancer of the Liver Italian
Program scores modified with the ALBI (albumin-bilirubin) grade, [17] [18] [19] vascular invasion and extrahepatic spread. All statistical analyses were performed with SAS statistical software (version 9.1.3; The SAS Institute, Cary, NC, USA). A two-sided P < .05 was considered significant.
3 | RESULTS
| Patient characteristics
From June 2012 to June 2014, 55 patients with advanced HCC were enrolled ( Figure 1 and Table 1 ). There was no significant difference in clinical characteristics between the whole cohort and the sub-groups of patients who were eligible for evaluation for individual biomarkers ( Table 1 ). All patients had received sorafenib and had documented disease progression after sorafenib treatment.
| Efficacy
As There were no specific clinical characteristics that could differentiate the 10 patients who obtained partial response or exhibited progressionfree survival more than 6 months from other subjects (Table S1 ). Four patients were alive at the end of follow-up, and two patient continued lenalidomide treatment (one remained in stable disease, and one used lenalidomide after documented tumour progression). 
| Exploratory biomarker study
Early a-fetoprotein response was found in 17 (43%) of 40 patients with elevated baseline a-fetoprotein ( Figure 2C ). Early a-fetoprotein response, compared with nonresponse, was associated with a higher disease-control rate (76% vs 22%, P = .001) ( Table 2) , longer progression-free survival (median, 5.4 vs 0.9 months, P = .020; Fig- ure 3A) and a higher response rate (29% vs 4%, P = .067). Multivariate analysis indicated that early a-fetoprotein response was an independent predictor for better progression-free survival and overall survival ( Figure 3A and 3B). Vascular response was found in 14 (32%) of 44 evaluable patients by dynamic contrast-enhanced MRI ( Figure 2D ). However, it was not associated with tumour response or survival (Table 2 , Figure 3C and 3D).
The percentage of lymphocyte subsets in the peripheral blood of all patients at baseline was summarised in Table S2 . Patients with high ( > the median of the percentage among all CD45 + cells) B cells at baseline, compared with patients with low ( ≤ median) B cells, were significantly more likely to have disease control (70% vs 36%, P = .010) ( Table 2 ) and longer progression-free survival (median, 3.6 vs 0.9 months, P < .001; Figure 3E ) and overall survival (median, 9.5 vs 7.1 months, P = .042; Figure 3F ). In multivariate analysis, the pretreatment B cell percentage remained an independent predictor for progression-free survival and overall survival ( Figure 3E and 3F ).
Regarding the changes after lenalidomide treatment, patients with increased NK-T cells after lenalidomide treatment exhibited significantly longer progression-free survival (median, 3.7 vs 1.6 months, P = .030; Figure 3G ) and overall survival (median, 10.5 vs 7.9 months, P = .049; Figure 3H ) compared with patients with decreased NK-T cells. However, the changes in NK-T cells were not associated with response rate or disease control (Table 2 ). In multivariate analysis, the post-treatment changes in NK-T cells remained an independent predictor for progression-free survival and overall survival ( Figure 3G and 3H) . No other baseline levels or post-treatment changes of lymphocyte subsets were associated with progression-free or overall survival (Table S2 ).
All of the identified mutations from available tumour samples in 30 (55%) patients are listed in Table S3 . For nonsynonymous exon mutations, MET mutations, which occurred in 2 (6.7%) patients and resulted in early termination at codon 171 and frameshift from codon 1259, respectively, was the only mutations that were associated with poor progression-free survival (HR 6.450, P = .002; Figure S1A ) and overall survival (HR 19.085, P < .001; Figure S1B ). In multivariate analysis,
MET mutations remained associated with poor overall survival (HR 16.692, P = .013), but not PFS. One patient had NRAS mutation, which caused frameshift from codon 129 and was associated with poor overall survival (HR 13.992, P = .031). It was not an independent predictor for progression-free or overall survival in multi-variate analysis.
For non-exonic mutations, CSF1R mutations, found at the 3' HR 0.350, P = .011), but not overall survival (Table S3 ). In multivariate analysis, none of these mutations remained independent predictors for progression-free or overall survival.
| Adverse events
All 55 patients were evaluable for adverse events. Twenty-eight (51%) patients escalated to continuous dosing of lenalidomide for a median duration of treatment of 4.2 months (range 0.9-29.8+). The clinical characteristics of these 28 patients did not differ significantly from those who did not use continuous dosing (Table S4 ). The incidence and severity of treatment related adverse events were consistent with previous reports of lenalidomide in other cancer types (Table S5) . Treatment interruption was needed in 26 (47%), and dose reduction was needed in 10 (18%) patients. The most common causes of dose interruption or reduction included neutropenia (n = 16), elevated transaminase level (n = 6), skin rash (n = 4), pruritus (n = 4) and infection (n = 3). Three (5%) patients discontinued the study treatment due to adverse events, including hyperbilirubinemia (n = 2) and neutropenia (n = 1).
| DISCUSSION
In this study, we found that lenalidomide has modest anti-tumour efficacy as second-line therapy for patients with advanced HCC, and the safety profile is similar to those previously reported. 20 The response rate and survival found in our study were consistent with those reported in the phase 2 trial conducted in the USA. 14 Early afetoprotein response may serve as a surrogate efficacy marker, as previously reported for various targeted therapies for HCC. [21] [22] [23] [24] [25] [26] Our exploratory biomarker studies also imply that the immune-modulatory effects of lenalidomide may play important roles in the antitumour effects of lenalidomide for HCC.
The best characterised immune-modulatory mechanism of lenalidomide is its binding with cereblon, an E3 ubiquitin ligase, and the degradation of transcription factors Ikaros and Aiolos. This leads to T cell activation, promotion of Th1 T cell differentiation, and repair of defects in immune synapse formation. 10, 11 We have also found that lenalidomide can enhance cytotoxic T cell activity in the tumour micro-environment using an orthotopic liver cancer mouse model. 27 The potential effects of lenalidomide on other immune cells remain undetermined, and many analogs of lenalidomide have been developed to pursue better immune-modulatory efficacy. Angiogenesis inhibition is a critical mechanism by which regorafenib and sorafenib exert their anti-tumour effects on HCC.
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Other anti-angiogenic agents, including ramucirumab, brivanib and axitinib, can also improve progression-free survival, but not overall survival, of HCC patients in the second-line setting. 34, 35 The potential therapeutic benefit may be further improved by identifying patients whose tumours are most likely to respond to anti-angiogenic therapy. Dynamic contrast-enhanced imaging has been , evaluated by dynamic contrast-enhanced MRI, from baseline after 2 wk of treatment.
extensively investigated to correlate the changes in blood volume and vascular permeability in tumours with efficacy of anti-angiogenic therapy. 36 We previously reported that vascular response, indicated by a decrease in K trans after treatment, correlated with better survival for HCC patients who received sorafenib-based therapy. 16, 37 Although lenalidomide can induce vascular response in about 30% of our patients, the lack of correlation with any efficacy parameters implies that lenalidomide may exert its anti-tumour effects on HCC independent of its anti-angiogenic effects.
The incidence of individual mutations of specific oncogenes/ tumour suppressor genes in HCC is generally low and many molecular aberrations, like c-MET may serve as both prognostic and predictive biomarkers. 38 The tumour-immune cell interaction has been an area of intense research, using the rapidly advancing immunogenomic tools. 39 For example, in melanoma Wnt/b-catenin activation was found to reduce recruitment of dendritic cells and cytotoxic T cell into tumour micro-environment and lead to impaired efficacy of checkpoint inhibitor therapy. 40 In nonsmall cell lung cancer, the activating mutations of the epidermal growth factor receptor were associated with lack of efficacy of immune checkpoint inhibitor therapy. 41 c-MET mutations were associated with both increased cancer invasion/metastases potential and drug resistance in various cancer models. 42 The roles of non-exonic mutations, such as the colony stimulating factor-1 receptor mutations found in this study, are more questionable. Whether these mutations were associated with efficacy of lenalidomide or other immunotherapy needs to be further explored.
In conclusion, we found that lenalidomide was safe and with modest activity for patients with advanced HCC. Its immunomodulatory effect and potential biomarkers should be further explored.
